about
Real-time, portable genome sequencing for Ebola surveillanceResurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 DaysEvaluation of RealStar Reverse Transcription–Polymerase Chain Reaction Kits for Filovirus Detection in the Laboratory and FieldEfficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Unusual Ebola Virus Chain of Transmission, Conakry, Guinea, 2014-2015Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaStudy of camelpox virus pathogenesis in athymic nude miceHow to treat Ebola virus infections? A lesson from the field.Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child.Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis.Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovirDifferent features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections.A single vertebrate DNA virus protein disarms invertebrate immunity to RNA virus infection.Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.Unique human immune signature of Ebola virus disease in Guinea.Emergence of cowpox: study of the virulence of clinical strains and evaluation of antiviralsMutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015KAY-2-41, a novel nucleoside analogue inhibitor of orthopoxviruses in vitro and in vivo.Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus.Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection.Camelpox virus.KSHV targeted therapy: an update on inhibitors of viral lytic replication.Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa.ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study.Identification of an interferon antagonist protein encoded by segment 7 of infectious salmon anaemia virus.Cidofovir treatment improves the pathology caused by the growth of human papillomavirus-positive cervical carcinoma xenografts in athymic nude mice.Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cellsInhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir.Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently.Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene.Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses.Antiherpesvirus activities of two novel 4'-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases.Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.Substrate specificity of homogeneous monkeypox virus uracil-DNA glycosylase.Identification of the Type of Cells Responsible for Transfer of Herpes Simplex Virus (HSV) and Vaccinia Virus (VACV) Infection to Epithelial Cells Grown in 3DSelection and Characterization of (S)-1-[3-Hydroxy-2-(Phosphonomethoxypropyl)-2,6-Diaminopurine [HPMPDAP] Resistant Camelpox Viruses
P50
Q24283957-444EB7E4-D800-4B0F-8379-5597F62AC7BFQ26738840-B113249D-410D-4C66-8258-63C6720AD93CQ27468621-00523113-7487-4CCE-ACFF-38D427EFC22BQ28051937-8E029B3C-6351-4721-B7D7-FAEFD2CF004FQ28051937-FD349CED-1181-4894-AF3A-3BE8CDFE8362Q28397333-1F2FC92F-D97E-4EB6-91D8-715497BA6C64Q28550455-D4FFC84D-5123-4982-9B61-D519090C4B77Q28743156-AFBCBA3E-2EE0-48A7-985F-7E86F2C5E348Q30234799-3B811EBF-9A54-4C16-BF22-48BCFFF8F1F6Q33603036-743C8016-DEA8-4258-9546-7F8FF4FA496DQ33632176-B633ED8C-1BD6-48B8-89DC-031484DC106FQ33643453-F78A8E00-CAC0-40D2-AEBC-CB06F171889CQ33803364-1614E960-436C-4245-894D-BD34E7CE9369Q33957049-69D5FB11-9A0A-4E21-8214-B419A6E1E396Q34488529-30CFF214-40CE-4D63-AB1F-23C36CED4D26Q34525050-36B2813E-2A80-4906-A9BA-16B5D92B6C96Q34606386-3214B9F9-3542-4C25-AF4C-6302A9DA92E4Q36155574-FECF04F0-5EF1-4169-A4F5-F54AF6C12A39Q37310771-8D3FBA69-32FF-4934-BFD9-289B69EBAC7FQ37544535-22CA3E40-B528-4FFD-837D-33C9F1D034EAQ37593571-02FDC8D9-14BA-4B94-8785-1CDFA3F4E4E8Q37700309-7C1AA503-EE55-4D50-8644-44A5B825BD43Q37938283-F8A41709-6938-4EF7-A1C4-A51B6AEA507BQ38271135-4A51F62F-36AD-4F41-86EB-C819D591C7D4Q38933098-D310A076-172D-4B5F-BEAC-84F1A60B7887Q39046951-A72361C5-D13D-4915-BF55-520C7A90E042Q39108103-80104419-3712-43D7-94A1-B070CFB59359Q39131439-E3AEEE5E-DF0B-4878-9282-F4F5DFDC53E9Q39246898-72438888-2BDA-408E-B9B7-2F1ED0A8C2B2Q39351834-4117B150-FDF7-4759-A9ED-F3E4823DE508Q39869286-8BA33ADC-CD20-4E9C-B276-119160733688Q39887221-1E3952C1-A71B-437F-8C17-F56CC8D1A364Q39969241-0F9B3B54-23FB-4C8F-A573-ABEAD1EC603AQ40076690-8DCE3B83-6F8D-4687-82EB-E502D26A7138Q41722018-3D773FA9-3CC5-4E92-B1FD-974086886D8DQ42109765-B13AC94A-1D5F-49A5-A17A-AF99C322E637Q42916550-76DA9B0E-3B54-46AF-B6AD-3583B84E381AQ44594293-7AF4F893-01E1-4057-A729-D9E23A7F4A96Q45399879-F927DDA8-3F08-4136-94F0-6F6FC0CBE47EQ57241260-B01CF146-9CAA-4378-8C0C-6B91B5EE200E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sophie Duraffour
@ast
Sophie Duraffour
@en
Sophie Duraffour
@es
Sophie Duraffour
@nl
Sophie Duraffour
@sl
type
label
Sophie Duraffour
@ast
Sophie Duraffour
@en
Sophie Duraffour
@es
Sophie Duraffour
@nl
Sophie Duraffour
@sl
prefLabel
Sophie Duraffour
@ast
Sophie Duraffour
@en
Sophie Duraffour
@es
Sophie Duraffour
@nl
Sophie Duraffour
@sl